Moore Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Moore Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-600,000	Closed	-$9.95M	–	771
2025 Q4	$9.95M	Hold	600,000	–	–	0.14%	162
2025 Q3	$7.06M	Hold	600,000	–	–	0.1%	193
2025 Q2	$5.75M	Buy	+600,000	New	+$3.32M	0.07%	201
2024 Q4	–	Sell	-130,000	Closed	-$2.35M	–	596
2024 Q3	$2.35M	Buy	130,000 +10,000	+8%	+$140K	0.04%	290
2024 Q2	$1.24M	Hold	120,000	–	–	0.02%	295
2024 Q1	$1.27M	Buy	120,000 +20,000	+20%	+$170K	0.02%	289
2023 Q4	$913K	Buy	100,000 +20,000	+25%	+$172K	0.02%	283
2023 Q3	$830K	Buy	80,000 +20,000	+33%	+$274K	0.02%	309
2023 Q2	$859K	Buy	+60,000	New	+$692K	0.01%	318

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Moore Capital Management's PHAT Position: Q1 2026 in Review

Moore Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 600,000 shares — an estimated $9.95M sold.

Moore Capital Management first reported a position in PHAT in Q2 2023 and held it in 9 quarters. The position peaked at $9.95M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

Moore Capital Management reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 600,000 Phathom Pharmaceuticals shares in Q1 2026, an estimated $9.95M.
Moore Capital Management first reported a position in Phathom Pharmaceuticals in Q2 2023 and held it in 9 quarters.
Moore Capital Management's Phathom Pharmaceuticals position peaked at $9.95M in Q4 2025.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.